2024
- In 2024, our faculty published more than 292 peer-reviewed publications highlighting innovative research findings and discoveries with 133 first or senior author papers.
- Overall awards for Aflac-associated researchers totaled nearly $32 million
- Highlights included:
- Continued IDIQ Contract funding for RADx - $5.5 million received in FY24 (Wilbur Lam)
- $800k Investment to become a Sickle Cell Transplant Research and Advocacy Alliance (STAR) Coordinating Center (Beth Stenger)
- R50 Award to establish an adolescent-young adult lymphoma program (Sharon Castellino)
2023
- In 2023, our faculty published more than 291 peer-reviewed publications highlighting innovative research findings and discoveries with 150 first or senior author papers.
- Overall awards for Aflac-associated researchers totaled nearly $110 million
- Highlights included:
- IDIQ Contract from the NIH to serve as the primary diagnostic test validation center - $49.8 million received in FY23 (Wilbur Lam)
- CURE Childhood Cancer $1.5 million grant to support Aflac's Precision Medicine Program (Sharon Castellino, Kelly Goldsmith, Tobey MacDonald, Chris Porter, and Ryan Summers)
- Katz Foundation $5 million grant to support Sickle Cell Disease quality initiatives (Beatrice Gee)
Meet the Team
Douglas Graham, MD, PhD
Center Director of Aflac Cancer and Blood Disorders Center
Dan Wechsler, MD, PhD
Section Chief of Oncology
Muna Qayed, MD
Interim Co-Director of Marcus Center for Cellular Therapy, Section Chief of BMT